Publication:
Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia

Simple item page
dc.contributor.authorTUĞLULAR, AYŞE TÜLİN
dc.contributor.authorsKockan, Betul; Toptas, Tayfur; Atagunduz, Isik; Tuglular, Ayse Tulin; Ozer, Ayse; Akkiprik, Mustafa
dc.date.accessioned2022-03-14T09:03:37Z
dc.date.available2022-03-14T09:03:37Z
dc.date.issued2017-12-13
dc.description.abstractThe present study aimed to detect the frequency of kinase domain (KD) mutations in order to evaluate their clinical significance and functional importance in 45 patients with chronic myeloid leukemia (CML) who were resistant to imatinib therapy. Sanger sequencing was used (45 patients), along with allele-specific oligonucleotide polymerase chain reaction (ASO-PCR; 3 patients), for the screening of mutations. BCR/ABL KD was amplified by nested PCR and sequencing was performed. Secondly, ASO-PCR was performed to confirm the results of the sequence analysis for E255K mutations. Mutations were detected in 11/45 patients (24.44%) via Sanger sequencing. D241G (4.4%), C369C (4.4%), K285N (2.2%), A380T (2.2%) and A366V (2.2%) mutations were detected. E255K (8.8%) was detected by ASO-PCR and Sanger sequencing. Mutations are a primary reason for suboptimal responses, loss of response and resistance to imatinib. In particular, the E255K mutation, which is characterized by resistance to imatinib and nilotinib, was detected in four patients. Analyzing the mutations and monitoring patients with CML may improve their prognosis and survival rate. ASO-PCR assays will be beneficial for the routine monitoring of mutations.
dc.identifier.doi10.3892/ol.2017.7606
dc.identifier.eissn1792-1082
dc.identifier.issn1792-1074
dc.identifier.pubmed29434953
dc.identifier.urihttps://hdl.handle.net/11424/242304
dc.identifier.wosWOS:000426145100052
dc.language.isoeng
dc.publisherSPANDIDOS PUBL LTD
dc.relation.ispartofONCOLOGY LETTERS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectchronic myeloid leukaemia
dc.subjectbreakpoint cluster region abelson kinase domain
dc.subjectmutation
dc.subjectimatinib resistance
dc.subjectDNA sequencing
dc.subjectKINASE DOMAIN MUTATIONS
dc.subjectDYNAMICS
dc.subjectMUTANTS
dc.subjectALLELE
dc.titleMolecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia
dc.typearticle
dspace.entity.typePublication
local.avesis.idf405a0dd-7dcf-4dd2-af42-0979881d20a7
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
local.journal.quartileQ4
oaire.citation.endPage2424
oaire.citation.issue2
oaire.citation.startPage2419
oaire.citation.titleONCOLOGY LETTERS
oaire.citation.volume15
relation.isAuthorOfPublicationce199cf0-d1ca-4741-84b3-ba3cf19c1358
relation.isAuthorOfPublication.latestForDiscoveryce199cf0-d1ca-4741-84b3-ba3cf19c1358

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ko�kan et al. - 2017 - Molecular screening and the clinical impacts of BC.pdf
Size:
818.98 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs